Xu Jianxiong, Gao Chen
Department of Radiation Oncology, The First Hospital of Putian City, Putian, Fujian, China.
Clinical Oncology School of Fujian Medical University & Fujian Cancer Hospital, Fuzhou, Fujian, China.
Discov Oncol. 2025 May 8;16(1):691. doi: 10.1007/s12672-025-02550-y.
The treatment of papillary thyroid carcinoma (PTC) presents ongoing challenges, underscoring the need for novel therapeutic targets.
This study employed proteomic MR analysis, utilizing publicly available data from genome-wide association studies (GWAS) and protein quantitative trait loci (pQTL) studies. We analyzed proteomic data from deCODE and the UK Biobank Protein Project (UKB-PP), along with GWAS data on papillary thyroid carcinoma (PTC) from the Finnish Consortium. This analysis was further supported by eQTL validation and bioinformatics differential analysis to identify potential therapeutic targets for PTC. Additionally, we explored possible downstream mechanisms of the target proteins through mediation analysis.
Our analysis identified two potential therapeutic targets associated with PTC, specifically, LY75 and S100A12. Mediation analysis further investigated their potential mechanistic role in the pathogenesis of PTC.
Through multi-omics analysis, we identified new potential therapeutic targets for papillary thyroid carcinoma and investigated their possible underlying mechanisms affecting PTC.
甲状腺乳头状癌（PTC）的治疗面临持续挑战，凸显了对新型治疗靶点的需求。
本研究采用蛋白质组学MR分析，利用来自全基因组关联研究（GWAS）和蛋白质数量性状位点（pQTL）研究的公开可用数据。我们分析了来自deCODE和英国生物银行蛋白质项目（UKB-PP）的蛋白质组学数据，以及来自芬兰财团的甲状腺乳头状癌（PTC）的GWAS数据。通过eQTL验证和生物信息学差异分析进一步支持了该分析，以确定PTC的潜在治疗靶点。此外，我们通过中介分析探索了靶蛋白可能的下游机制。
我们的分析确定了两个与PTC相关的潜在治疗靶点，具体为LY75和S100A12。中介分析进一步研究了它们在PTC发病机制中的潜在机制作用。
通过多组学分析，我们确定了甲状腺乳头状癌新的潜在治疗靶点，并研究了它们影响PTC的可能潜在机制。
